Compare LyondellBasell Industries NV (LYB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Novo Nordisk A/S — how do they compare? LyondellBasell Industries NV trades at $62.66 (market cap $20.67B), while Novo Nordisk A/S trades at $46.23 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 10.1× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays the higher dividend (6.44%). Which is the better fit depends on your goals.
| LYB | NVO | |
|---|---|---|
Market Cap | $20.67B | $207.85B |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $63.98 |
52-Week Low | $42.28 | $35.29 |
Enterprise Value | $32.26B | $222.55B |
Dividend Yield | 6.44% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYB trades at $62.97, up 0.51% today, with a bullish technical signal from moving averages and a consensus analyst price target of $70.56. Recent Q2 2026 earnings of $4.30 per share beat estimates, driven by improved margins from supply disruptions and cost cuts. However, 2025 fundamentals show declining revenue to $30.15B and a net loss of $745M, though cash flow remains positive. The stock is near its 52-week high of $83.94, reflecting optimism around operational improvements.
Outlook: Near-term upside exists from earnings momentum and favorable supply dynamics, but risks include volatile chemical margins and high debt. Analyst sentiment is mixed with 46% buy ratings, suggesting cautious optimism amid cyclical challenges.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
